Un-Audited Financial Results for the Third quarter and Nine months ended December 31, 2025, along with the Statutory Auditors Limited Review Report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 2.2 pts more than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natural Biocon reported zero net sales in Q3 FY26 (Oct–Dec 2025), down sharply from Rs 127.73 lakhs in the same quarter last year. For the nine months ended December 2025, total revenue fell to Rs 166.57 lakhs from Rs 601.42 lakhs in 9M FY25, a drop of about 72%. The company slipped into a loss of Rs 4.27 lakhs in Q3 FY26, compared with a profit of Rs 24.59 lakhs a year ago; Q2 FY26 also had zero revenue and a Rs 4.37 lakh loss. Basic and diluted EPS for Q3 FY26 stood at Rs (0.02). The auditor (Mayur Shah & Associates) issued an unqualified limited review report, finding nothing that suggests the results are misstated.
Two back-to-back quarters of zero revenue signal a serious business slowdown that shareholders should monitor closely, even though the absolute losses remain small relative to the company's equity base.